PMV Pharma 8-K Signals Exit/Disposal Costs, Reg FD Disclosure

TL;DR

**PMVP filed an 8-K on Jan 18, 2024, indicating costs from exiting or disposing of activities, which could hit financials.**

AI Summary

PMV Pharmaceuticals, Inc. filed an 8-K on January 18, 2024, to report an event related to 'Cost Associated with Exit or Disposal Activities' and 'Regulation FD Disclosure'. This filing indicates that the company is likely undergoing some form of restructuring or winding down certain operations, which could involve significant costs. For investors, this matters because such activities can impact the company's financial health, potentially leading to one-time charges that affect profitability and future growth prospects, making the stock a riskier investment.

Why It Matters

This filing suggests PMV Pharmaceuticals is incurring costs related to exiting or disposing of certain activities, which could signal a strategic shift or operational downsizing impacting future financial performance.

Risk Assessment

Risk Level: medium — The mention of 'Cost Associated with Exit or Disposal Activities' introduces uncertainty about the company's future operations and financial stability.

Analyst Insight

A smart investor would investigate the specific nature and magnitude of the 'Cost Associated with Exit or Disposal Activities' mentioned in the filing to understand the potential financial impact on PMV Pharmaceuticals, Inc. before making any investment decisions.

Key Players & Entities

• PMV Pharmaceuticals, Inc. (company) — the registrant filing the 8-K
• January 18, 2024 (date) — date of earliest event reported and filing date
• 001-39539 (number) — Commission File Number for PMV Pharmaceuticals, Inc.
• PMVP (company) — trading symbol for PMV Pharmaceuticals, Inc.
• The Nasdaq Global Select Market (company) — exchange where PMVP common stock is registered

FAQ

Key Financial Figures

• $0.00001 — nge on which registered Common Stock, $0.00001 par value per share PMVP The Nasdaq
• $1.4 m — non-recurring charges of approximately $1.4 million, consisting primarily of employee

Filing Documents

• d695291d8k.htm (8-K) — 29KB
• d695291dex991.htm (EX-99.1) — 11KB
• 0001193125-24-010177.txt ( ) — 160KB
• pmvp-20240118.xsd (EX-101.SCH) — 3KB
• pmvp-20240118_lab.xml (EX-101.LAB) — 17KB
• pmvp-20240118_pre.xml (EX-101.PRE) — 11KB
• d695291d8k_htm.xml (XML) — 3KB

05 Costs Associated with Exit or Disposal Activities

Item 2.05 Costs Associated with Exit or Disposal Activities. On January 18, 2024, PMV Pharmaceuticals, Inc. (the " Company ") announced a restructuring plan involving the reduction of its workforce by approximately 30% of the Company's employees. The Company expects the reduction in workforce to be substantially completed by June 30, 2024, and fully completed by the end of the third quarter of 2024. The Company is taking these steps in order to streamline operations, reduce costs and preserve capital as it advances into late-stage development for its lead product candidate, PC14586. As a result of the reduction in force, the Company expects to incur aggregate non-recurring charges of approximately $1.4 million, consisting primarily of employee severance and benefit costs associated with the restructuring. The Company expects that most of these charges will be cash expenditures and that it will recognize the majority of these charges in the first quarter of 2024. The estimated charges that the Company expects to incur are subject to a number of assumptions, and actual expenses may differ materially from these estimates. The Company may also incur additional costs not currently contemplated due to unanticipated events that may occur as a result of, or that are associated with, its plan. Cautionary Note Regarding Forward-Looking Statements

01 Regulation FD Disclosure

Item 7.01 Regulation FD Disclosure. On January 18, 2024, the Company issued a press release, a copy of which is furnished as Exhibit 99.1 to this Current Report on Form 8-K and incorporated herein by reference. The information in this Item 7.01 and Exhibit 99.1 attached hereto is intended to be furnished and shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the " Exchange Act "), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference to such filing.

01 Financial Statements and Exhibits

Item 9.01 Financial Statements and Exhibits. (d) Exhibits : Exhibit Number Description 99.1 Press Release issued by PMV Pharmaceuticals, Inc., dated January 18, 2024. 104 Cover Page Interactive Data File (embedded within the Inline XBRL document).

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized. PMV Pharmaceuticals, Inc. Date: January 18, 2024 By: /s/ Michael Carulli Michael Carulli Chief Financial Officer

View Full Filing

View this 8-K filing on SEC EDGAR